168 related articles for article (PubMed ID: 31402615)
1. Benign tumors in myotonic dystrophy type I target disease-related cancer sites.
Alsaggaf R; St George DMM; Zhan M; Pfeiffer RM; Wang Y; Anderson LA; Liu Z; Koshiol J; Bauer AJ; Wagner KR; Greene MH; Amr S; Gadalla SM
Ann Clin Transl Neurol; 2019 Aug; 6(8):1510-1518. PubMed ID: 31402615
[TBL] [Abstract][Full Text] [Related]
2. Diabetes, metformin and cancer risk in myotonic dystrophy type I.
Alsaggaf R; Pfeiffer RM; Wang Y; St George DMM; Zhan M; Wagner KR; Amr S; Greene MH; Gadalla SM
Int J Cancer; 2020 Aug; 147(3):785-792. PubMed ID: 31749144
[TBL] [Abstract][Full Text] [Related]
3. Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink.
Wang Y; Pfeiffer RM; Alsaggaf R; Meeraus W; Gage JC; Anderson LA; Bremer RC; Nikolenko N; Lochmuller H; Greene MH; Gadalla SM
Int J Cancer; 2018 Mar; 142(6):1174-1181. PubMed ID: 29114849
[TBL] [Abstract][Full Text] [Related]
4. Correlates of tumor development in patients with myotonic dystrophy.
Das M; Moxley RT; Hilbert JE; Martens WB; Letren L; Greene MH; Gadalla SM
J Neurol; 2012 Oct; 259(10):2161-6. PubMed ID: 22619053
[TBL] [Abstract][Full Text] [Related]
5. Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity.
Alsaggaf R; St George DMM; Zhan M; Pfeiffer RM; Wang Y; Wagner KR; Greene MH; Amr S; Gadalla SM
JNCI Cancer Spectr; 2018 Nov; 2(4):pky052. PubMed ID: 30556050
[TBL] [Abstract][Full Text] [Related]
6. [Increasing risk of tumors in myotonic dystrophy type 1].
Mohamed S; Pruna L; Kaminsky P
Presse Med; 2013 Sep; 42(9 Pt 1):e281-4. PubMed ID: 23477718
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification.
De Antonio M; Dogan C; Hamroun D; Mati M; Zerrouki S; Eymard B; Katsahian S; Bassez G;
Rev Neurol (Paris); 2016 Oct; 172(10):572-580. PubMed ID: 27665240
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors.
Bianchi ML; Leoncini E; Masciullo M; Modoni A; Gadalla SM; Massa R; Rastelli E; Terracciano C; Antonini G; Bucci E; Petrucci A; Costanzi S; Santoro M; Boccia S; Silvestri G
J Neurol; 2016 Mar; 263(3):492-8. PubMed ID: 26739382
[TBL] [Abstract][Full Text] [Related]
9. Cardiac involvement in myotonic dystrophy: a nationwide cohort study.
Lund M; Diaz LJ; Ranthe MF; Petri H; Duno M; Juncker I; Eiberg H; Vissing J; Bundgaard H; Wohlfahrt J; Melbye M
Eur Heart J; 2014 Aug; 35(32):2158-64. PubMed ID: 24742887
[TBL] [Abstract][Full Text] [Related]
10. Survival patterns and cancer determinants in families with myotonic dystrophy type 1.
Best AF; Hilbert JE; Wood L; Martens WB; Nikolenko N; Marini-Bettolo C; Lochmüller H; Rosenberg PS; Moxley RT; Greene MH; Gadalla SM
Eur J Neurol; 2019 Jan; 26(1):58-65. PubMed ID: 30051542
[TBL] [Abstract][Full Text] [Related]
11. Peripheral nerve involvement in myotonic dystrophy type 2 - similar or different than in myotonic dystrophy type 1?
Nojszewska M; Łusakowska A; Szmidt-Salkowska E; Gaweł M; Lipowska M; Sułek A; Krysa W; Rajkiewicz M; Seroka A; Kaczmarek K; Kamińska AM
Neurol Neurochir Pol; 2015; 49(3):164-70. PubMed ID: 26048604
[TBL] [Abstract][Full Text] [Related]
12. On oral health in children and adults with myotonic dystrophy.
Engvall M
Swed Dent J Suppl; 2010; (203):1-51. PubMed ID: 20514921
[TBL] [Abstract][Full Text] [Related]
13. Increased cancer risks in myotonic dystrophy.
Win AK; Perattur PG; Pulido JS; Pulido CM; Lindor NM
Mayo Clin Proc; 2012 Feb; 87(2):130-5. PubMed ID: 22237010
[TBL] [Abstract][Full Text] [Related]
14. Cancer risk in DM1 is sex-related and linked to miRNA-200/141 downregulation.
Fernández-Torrón R; García-Puga M; Emparanza JI; Maneiro M; Cobo AM; Poza JJ; Espinal JB; Zulaica M; Ruiz I; Martorell L; Otaegui D; Matheu A; López de Munain A
Neurology; 2016 Sep; 87(12):1250-7. PubMed ID: 27558368
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of myotonic dystrophy type 1 (Steinert disease) in Belgrade (Serbia).
Mladenovic J; Pekmezovic T; Todorovic S; Rakocevic-Stojanovic V; Savic D; Romac S; Apostolski S
Clin Neurol Neurosurg; 2006 Dec; 108(8):757-60. PubMed ID: 16713671
[TBL] [Abstract][Full Text] [Related]
16. Oropharyngeal dysphagia in early stages of myotonic dystrophy type 1.
Franco-Guerrero AA; Márquez-Quiroz LC; Valadéz-Jiménez VM; Cortés H; Murillo-Melo NM; Muñoz B; Cisneros B; Magaña JJ
Muscle Nerve; 2019 Jul; 60(1):90-95. PubMed ID: 30994189
[TBL] [Abstract][Full Text] [Related]
17. Survival and mortality of myotonic dystrophy type 1 (Steinert's disease) in the population of Belgrade.
Mladenovic J; Pekmezovic T; Todorovic S; Rakocevic-Stojanovic V; Savic D; Romac S; Apostolski S
Eur J Neurol; 2006 May; 13(5):451-4. PubMed ID: 16722967
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular manifestations of myotonic dystrophy-1.
Sovari AA; Bodine CK; Farokhi F
Cardiol Rev; 2007; 15(4):191-4. PubMed ID: 17575483
[TBL] [Abstract][Full Text] [Related]
19. Benign and malignant tumors in the UK myotonic dystrophy patient registry.
Alsaggaf R; Wang Y; Marini-Bettolo C; Wood L; Nikolenko N; Lochmüller H; Greene MH; Gadalla SM
Muscle Nerve; 2018 Feb; 57(2):316-320. PubMed ID: 28662292
[TBL] [Abstract][Full Text] [Related]
20. Mutation analysis of multiple pilomatricomas in a patient with myotonic dystrophy type 1 suggests a DM1-associated hypermutation phenotype.
Rübben A; Wahl RU; Eggermann T; Dahl E; Ortiz-Brüchle N; Cacchi C
PLoS One; 2020; 15(3):e0230003. PubMed ID: 32155193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
